Boston is the apex of today’s biotechnology world. With over 250 companies in Boston, Cambridge, and surrounding suburbs, nearly every pharmaceutical company has a stake in Boston’s biotech network.
Alexander R. Ivanov’s paper, “Mass-Spectrometry-Based Molecular Characterization of Extracellular Vesicles: Lipidomics and Proteomics” was recognized by C&EN’s publication ‘Supplement” as one of the top ten chromatography and mass spectrometry papers.
A short course by Olga Vitek focused on how to keep up in the field of proteomics when the rapid advancements make it tough to interpret and translate meaningful results.
While on co-op at Woods Hole Oceanographic Institution in Cape Cod, Elliott Mueller is testing Martian meteorites and lunar samples from the Apollo missions.
In a paper published in Nature Chemistry, Northeastern University physics professor Paul Champion, uses ultrafast laser technology to determine how physics and chemistry combine to make biology happen.
Spencer Martin is working at Ernst & Young as part of the pharmaceuticals team, preparing for and performing mergers and acquisitions of Indian and multi-national pharmaceutical companies.
Amanda Dell’Olio is responsible for analyzing and maintaining the water quality throughout the Walt Disney World properties.
Isaac Kresse is working for SINTEF in Trondheim, Norway.
Tom Gilbert, Associate Professor of Chemistry and Chemical Biology, is one of two people vying to be president of the world’s largest scientific professional society.
Northeastern research professor K.M. Abraham goes inside the self-balancing scooters to reveal the science behind their combustion.